PRAGUE—HDL cholesterol (HDL) in patients with chronic kidney disease (CKD) loses its protective effect on vascular endothelium, new findings suggest. Rather than supporting the beneficial functions of the endothelium, it appears to become pro-inflammatory and inhibit them.
PRAGUE—A multifactorial intervention using a polydrug and lifestyle treatment strategy with nurse practitioner (NP) support can improve management of some cardiovascular (CV) risk factors and reduced the number of physician visits by patients with chronic kidney disease (CKD).
The drug was more likely than cinacalcet to achieve a 50 percent or greater decrease in iPTH from baseline.
PRAGUE—Transient hyponatremia may precede development of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography, according to investigators.
PRAGUE—End-stage renal disease patients who start on peritoneal dialysis (PD) rather than hemodialysis (HD) spend less time on a renal transplant waiting list before getting a kidney, new findings suggest.
PRAGUE—Renal transplant recipients who have anemia three months after receiving a kidney are more likely to have anemia more than six months post-transplant, according to researchers.
PRAGUE—Taking antihypertensive medications at bedtime significantly reduces cardiovascular disease (CVD) risk compared with ingesting the drugs upon awakening, according to researchers.
PRAGUE—Early referral patients who start dialysis with an estimated glomerular filtration rate (eGFR) below 6 mL/min/1.73 m2 are not at increased risk of death compared with those who start dialysis at an eGFR above 6, a study showed.
PRAGUE—A single four-week course of rituximab was as effective as 18 months of standard therapy with daily oral cyclophosphamide (CyP) and azathioprine (AZA) for induction and maintenance of remission in patients with severe anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). For either treatment, the number, rate, and severity of adverse events did not differ.
PRAGUE—Therapy with bardoxolone, an oral antioxidant inflammation modulator, is associated with improved kidney function out to one year in patients with advanced chronic kidney disease (CKD) and type 2 diabetes, according to investigators.
Please login or register first to view this content.
